MiNK Therapeutics, Inc.
NASDAQ:INKTBiotechnology
-$0.35 today
- Market cap
- $52.17M
- Beta
- 0.47
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$2.60
Volume 0.01M
Average 0.05M
INKT Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
MiNK Therapeutics, Inc.NASDAQ: INKT
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $36.07K fell 29.0% year over year, behind the +85472.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 100.0% from the prior quarter. Over 3 fiscal years it compounded at +14.3% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -29.0% toward the trailing-twelve-month pace of +85472.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 181.75K USD
- Year-over-year change
- -15.6%
- 4-year CAGR
- +23.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 181.75K | -15.6% |
| FY2024 | 2024-12-31 | 215.44K | +5.3% |
| FY2023 | 2023-12-31 | 204.62K | +68.1% |
| FY2022 | 2022-12-31 | 121.75K | +56.2% |
| FY2021 | 2021-12-31 | 77.96K | — |
Depreciation & Amortization vs competitors
How INKT compares with its peers on the latest reported figures
- INKT's LTM Mar 2026 depreciation & amortization of $181.73M is the 2nd largest of the 9 companies compared; the peer median is $193.32K.
- Its year-over-year change of +85472.1% is the 2nd highest of 9, against a peer median of +61.9%.
- Over three fiscal years its annual growth of +14.3% compares with a peer median of +6.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $363.33M | +106428.1% | +7569.0% | — |
| LTM Mar 2026 | $181.73M | +85472.1% | +14.3% | — | |
| LTM Jun 2026 | $3.65M | +111.3% | +14.0% | 17.4% | |
| LTM Mar 2026 | $305K | +6000.0% | +229.4% | 13.3% | |
| LTM Mar 2026 | $267K | +621.6% | -34.3% | — | |
| LTM Mar 2026 | $119.64K | +3.7% | -17.0% | 35.9% | |
| LTM Mar 2026 | $107K | -22.5% | -0.6% | — | |
| LTM Mar 2026 | $94.69K | +12.5% | +13.6% | — | |
| LTM Mar 2026 | $8K | -89.5% | -44.2% | 0.0% | |
| Peer median (excluding INKT) | $193.32K | +61.9% | +6.5% | 15.3% | |
Competitors are the stored peer set for INKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (30.21M) | (27.99M) | (22.46M) | (10.78M) | (12.49M) |
| Depreciation & Amortization | 77.96K | 121.75K | 204.62K | 215.44K | 181.75K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.74M | 3.03M | 3.86M | 1.81M | 2.67M |
| Change in Working Capital | 3.74M | 8.77M | 2.9M | 459.73K | 3.29M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (152.04K) | 2.66M | (1.92M) | (1.18M) | 689.71K |
| Other Working Capital | 3.89M | 6.11M | 4.81M | 1.64M | 2.6M |
| Other Non-Cash Items | 11.83M | (2.79M) | (266.78K) | (1.26M) | 424.63K |
| Operating Cash Flow | (12.83M) | (18.87M) | (15.76M) | (9.56M) | (5.93M) |
| Capital Expenditures | (248.98K) | (250.05K) | (73.56K) | (4) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (248.98K) | (250.05K) | (73.56K) | 0 | 0 |
| Debt Repayment | 9.46M | 0 | 0 | 5M | 0 |
| Common Stock Issued | 39.8M | 0 | 0 | 5.8M | 14.9M |
| Common Stock Repurchased | 0 | (157.19K) | (477.64K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 150 | 1.6K | 70.47K | 19.99K | (173.35K) |
| Financing Cash Flow | 49.26M | (155.6K) | (407.17K) | 10.82M | 14.72M |
| Effect of Forex Changes | 16.9K | 19.39K | (25.25K) | (54.7K) | (13.43K) |
| Net Change in Cash | 36.2M | (19.25M) | (16.27M) | 1.21M | 8.78M |
| Free Cash Flow | (13.08M) | (19.12M) | (15.84M) | (9.56M) | (5.93M) |
MiNK Therapeutics, Inc.
NASDAQ:INKT
Intrinsic Alpha fair value
Locked
Current Price
$10.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.